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Introduction: Interethnic variability of drug metabolism has been 
demonstrated across Iberoamerican populations by the CEIBA 
Consortium. Drug-metabolizing enzymes genotype just predicts 
actual drug metabolic activity (phenotype) in the cases of poor 
metabolizers. For example, only 30% of ultrarapid metabolizers 
can be predicted from genotyping (Llerena et al., 2012). Moreover, 
according to EMA recommendations, development of phenotyping 
procedures for drug interactions studies and clinical research recom-
mended (EMA, 2013). Therefore, a novel cocktail approach to meas-
ure metabolic activity (metabolic ratios) of the main CYP enzymes 
in just one experiment is developed and validated to be used in the 
study of Latin-American populations.
Patients (or Materials) and Methods: Subjects were given low 
oral doses of 100-mg caffeine, 25-mg losartan, 20-mg omepra-
zole, and 30-mg dextromethorphan. Blood samples were taken 4 
hours after administering the drugs to assay the following meta-
bolic ratios in plasma: CYP1A2 (caffeine/paraxanthine), CYP2C9 
(losartan /E-3174), CYP2C19 (omeprazole/5-hydroxyomepra-
zole), CYP2D6 (dextromethorphan/ dextrorphan), and CYP3A4 
(dextromethorphan/3-methoxymorphinan). Solid phase extraction 
was utilized for analyte extraction and LC-MS/MS to quantify the 
probe drugs and metabolites.
Results: Recovery values > 80% were obtained for all analytes, and 
no carryover or relative matrix effects were observed. The analytes 
were separated and detected in 9 minutes and the method was fully 
validated, with lower limits of quantification ranging from 0.3 ng 
mL–1 for 5-hydroxyomeprazole to 3.2 ng mL–1 for paraxanthine. 
The correlation coefficient (r2) values obtained were over 0.995 for 
all analytes. According to the EMA guideline on bioanalytical method 
validation, precision and accuracy values below 15% were achieved.
Conclusion: The method was proven to be useful to measure targeted 
analytes for the evaluation of CYPs hydroxylation capacity in just 
a single experiment.
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Introduction: VKORC1, CYP2C9, and CYP4F2 responsible for 
the metabolism of warfarin. Personal and ethnic differences in the 
genetic profile reveals in determining the outcome of a drug therapy. 
Aim: to explore the frequencies of CYP2C9, VCORC1, and CYP4F2 
genotypes in Russians, compare results with ones for other nations
Patients (or Materials) and Methods: A total 91 Caucasian subjects 
were recruited into the study. Forty (48.2%) patients were male and 
age was 66.17 (10.9) years. All patients had indications to receive 
warfarin. Medical records for the patients group were reviewed for 
the relevant clinical data. 5 ml of blood was taken from each subject, 
and DNA was isolated and used for identification of the CYP2C9 
allele *1, *2, *3; G-1639A VCORC1; CYP4F2 V433M rs2108622 
C > T using real-time polymerase chain reaction-restriction fragment 
length polymorphism assay. Results were compared with other ethnic 
groups and statistically analyzed with chi-square test.
Results: We described the prevalence of CYP2C9 polymorphisms *1/*1 
(67%), *1/*2 (9,9%), *1/*3 (11%), *2/*2 (2,2%), *2/*3 (8,8%), same 
for VKORC1 GG (49,5%), GA (28,6%), AA (22,%) and CYP4F2 CC 
(57,1%), CT (34,1%), TT (7,7%). No significant deviantions from 
Hardy-Wainberg equilibrium were observed (p < 0.05). Polymorphisms’ 
frequency of CYP2C9 (P < 0.001) and VKORC1 GG, AA (P < 0.05) in 
Russian distinguish from Asian. There are no significant interethnic vari-
ations for CYP4F2 between Russian, Asian and Caucasian (P > 0.05).
Conclusion: Prevalence of carriage of CYP2C9, VKORC1 polymor-
phisms in Russian patients with high thrombotic risk is closed to 
Caucasians and distinguish from Asians but no for CYP4F2.
Disclosure of Interest: None declared.
PP152—TenDenCy To higheR aCTiviTy of 
CyP3a5 in Women WiTh sTillbiRTh
K. Zagorodnikova*; M. Kondrahina; J. Rustanovich; and D. Kostyuchek
North-west State Medical University n.a.I.I.Mechnikov, St 
Petersburg, Russian Federation
Introduction: CYP3A5 is an enzyme known to be involved in metab-
olism of human hormones – progesterone and testosterone, which 
metabolism may play a role in either disease origin or treatment 
efficacy in women with stillbirth. There is a common genetic poly-
morphism leading to its increased activity (6986*> G). Our aim was 
to investigate possible role of this polymorphism in stillbirth.
Patients (or Materials) and Methods: All women admitted to gyne-
cology department of university clinics with verified diagnoses of still 
birth were considered for recruitment to the study. At the same time 
women who attended routine pregnancy registration were screened 
and recruited at the same time as the study group being matched by 
their age and concomitant diseases. All women who gave informed 
consent were recruited. Peripheral venous blood samples were drawn 
into EDTA tubes. Dna was extracted. Polymerase chain reaction in 
real time was performed to detect genetic variants of CYP3A5 *3/*1 
(6986*> G). Chi-square test was used for frequency comparisons 
using statistical software Graphpad Prizm 5.0.
Results: Fifty-three women with stillbirth were recruited to the study. 
Control group consisted of 92 matched women. Frequency of the minor 
